Molecular imaging of hypoxia in non-small cell lung cancer

Connie Yip; Philip Blower; Vicky Goh; David Landau; Gary Cook

doi:10.1007/s00259-015-3009-6

Molecular imaging of hypoxia in non-small cell lung cancer

Connie Yip, Philip Blower, Vicky Goh, David Landau, Gary Cook

Research output: Contribution to journal › Article › peer-review

45 Citations (Scopus)

Abstract

Non-small-cell lung cancer (NSCLC) is the commonest cancer worldwide but survival remains poor with a high risk of relapse, particularly after nonsurgical treatment. Hypoxia is present in a variety of solid tumours, including NSCLC. It is associated with treatment resistance and a poor prognosis, although when recognised may be amenable to different treatment strategies. Thus, noninvasive assessment of intratumoral hypoxia could be used to stratify patients for modification of subsequent treatment to improve tumour control. Molecular imaging approaches targeting hypoxic cells have shown some early success in the clinical setting. This review evaluates the evidence for hypoxia imaging using PET in NSCLC and explores its potential clinical utility.

Original language	English
Pages (from-to)	956-976
Number of pages	21
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	42
Issue number	6
Early online date	21 Feb 2015
DOIs	https://doi.org/10.1007/s00259-015-3009-6
Publication status	Published - May 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00259-015-3009-6

Cite this

@article{45ee67d22f3d43e7bb5ee8347c3ccd29,

title = "Molecular imaging of hypoxia in non-small cell lung cancer",

abstract = "Non-small-cell lung cancer (NSCLC) is the commonest cancer worldwide but survival remains poor with a high risk of relapse, particularly after nonsurgical treatment. Hypoxia is present in a variety of solid tumours, including NSCLC. It is associated with treatment resistance and a poor prognosis, although when recognised may be amenable to different treatment strategies. Thus, noninvasive assessment of intratumoral hypoxia could be used to stratify patients for modification of subsequent treatment to improve tumour control. Molecular imaging approaches targeting hypoxic cells have shown some early success in the clinical setting. This review evaluates the evidence for hypoxia imaging using PET in NSCLC and explores its potential clinical utility.",

author = "Connie Yip and Philip Blower and Vicky Goh and David Landau and Gary Cook",

year = "2015",

month = may,

doi = "10.1007/s00259-015-3009-6",

language = "English",

volume = "42",

pages = "956--976",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "SPRINGER",

number = "6",

}

TY - JOUR

T1 - Molecular imaging of hypoxia in non-small cell lung cancer

AU - Yip, Connie

AU - Blower, Philip

AU - Goh, Vicky

AU - Landau, David

AU - Cook, Gary

PY - 2015/5

Y1 - 2015/5

N2 - Non-small-cell lung cancer (NSCLC) is the commonest cancer worldwide but survival remains poor with a high risk of relapse, particularly after nonsurgical treatment. Hypoxia is present in a variety of solid tumours, including NSCLC. It is associated with treatment resistance and a poor prognosis, although when recognised may be amenable to different treatment strategies. Thus, noninvasive assessment of intratumoral hypoxia could be used to stratify patients for modification of subsequent treatment to improve tumour control. Molecular imaging approaches targeting hypoxic cells have shown some early success in the clinical setting. This review evaluates the evidence for hypoxia imaging using PET in NSCLC and explores its potential clinical utility.

AB - Non-small-cell lung cancer (NSCLC) is the commonest cancer worldwide but survival remains poor with a high risk of relapse, particularly after nonsurgical treatment. Hypoxia is present in a variety of solid tumours, including NSCLC. It is associated with treatment resistance and a poor prognosis, although when recognised may be amenable to different treatment strategies. Thus, noninvasive assessment of intratumoral hypoxia could be used to stratify patients for modification of subsequent treatment to improve tumour control. Molecular imaging approaches targeting hypoxic cells have shown some early success in the clinical setting. This review evaluates the evidence for hypoxia imaging using PET in NSCLC and explores its potential clinical utility.

U2 - 10.1007/s00259-015-3009-6

DO - 10.1007/s00259-015-3009-6

M3 - Article

SN - 1619-7070

VL - 42

SP - 956

EP - 976

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - 6

ER -

Molecular imaging of hypoxia in non-small cell lung cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this